US EditionPublished • loading... • Updated
Cynata’s CYP-001 shows positive safety profile in kidney transplant trial
Summary by Stockhead
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Cynata’s CYP-001 shows positive safety profile in kidney transplant trial
Review of first cohort in Cynata’s phase 1/2 NEREID trial in kidney transplant patients successfully completed No safety concerns identified with trial cleared to progress to the next stage Trial managed and funded by global kidney transplant leader Leiden University Medical Centre in the Netherlands Special Report: Cynata Therapeutics has reported encouraging results from the first cohort of its phase 1/2 NEREID kidney transplant trial, with …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
